Brad Canino
Stock Analyst at Guggenheim
(4.31)
# 360
Out of 5,241 analysts
30
Total ratings
59.26%
Success rate
18.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $38 → $35 | $13.59 | +157.54% | 3 | May 13, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $42 | $20.23 | +107.61% | 1 | May 11, 2026 | |
| JANX Janux Therapeutics | Maintains: Buy | $68 → $58 | $13.89 | +317.57% | 3 | May 8, 2026 | |
| CELC Celcuity | Maintains: Buy | $135 → $165 | $137.68 | +19.84% | 2 | May 4, 2026 | |
| TYRA Tyra Biosciences | Initiates: Buy | $54 | $37.04 | +45.79% | 1 | Apr 15, 2026 | |
| RLAY Relay Therapeutics | Maintains: Buy | $15 → $22 | $12.20 | +80.33% | 2 | Mar 13, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $30 | $15.73 | +90.72% | 1 | Feb 2, 2026 | |
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $19.98 | +75.18% | 1 | Jan 21, 2026 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.75 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $102.30 | +51.52% | 2 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $7 | $2.28 | +207.02% | 2 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $90 | $82.21 | +9.48% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $16.87 | +137.11% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $66.93 | +34.47% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $8.15 | +120.86% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.56 | +124.72% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.22 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $23.93 | +129.84% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $50.13 | -40.16% | 2 | Mar 31, 2021 |
Olema Pharmaceuticals
May 13, 2026
Maintains: Buy
Price Target: $38 → $35
Current: $13.59
Upside: +157.54%
Bicara Therapeutics
May 11, 2026
Initiates: Buy
Price Target: $42
Current: $20.23
Upside: +107.61%
Janux Therapeutics
May 8, 2026
Maintains: Buy
Price Target: $68 → $58
Current: $13.89
Upside: +317.57%
Celcuity
May 4, 2026
Maintains: Buy
Price Target: $135 → $165
Current: $137.68
Upside: +19.84%
Tyra Biosciences
Apr 15, 2026
Initiates: Buy
Price Target: $54
Current: $37.04
Upside: +45.79%
Relay Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $22
Current: $12.20
Upside: +80.33%
Cullinan Therapeutics
Feb 2, 2026
Initiates: Buy
Price Target: $30
Current: $15.73
Upside: +90.72%
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $19.98
Upside: +75.18%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.75
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $102.30
Upside: +51.52%
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $2.28
Upside: +207.02%
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $82.21
Upside: +9.48%
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $16.87
Upside: +137.11%
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $66.93
Upside: +34.47%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $8.15
Upside: +120.86%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $3.56
Upside: +124.72%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $9.22
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $23.93
Upside: +129.84%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $50.13
Upside: -40.16%